UK Prostate Cancer Diagnostic and Therapeutic Market: Size, Share and Forecast 2019-2025

UK prostate cancer market is forecast to grow at a CAGR of 9.7% during the forecast period. The high incidence of prostate cancer is the major factor for augmenting the demand for prostate cancer diagnostics services and therapeutics in the country. As per the World Health Organization, around 56,000 new cases of prostate cancer were registered in 2018. It is the most common cancer in the country with around 24% of the overall new cancer cases in men. The 5-year prevalence in the country due to prostate cancer is around 206,000 in 2018.

To learn more about UK Prostate Cancer Diagnostic and Therapeutic Market report request a free sample copy @ https://www.omrglobal.com/request-sample/uk-prostate-cancer-diagnostic-therapeutic-market

In UK, prostate cancer is the second largest cause of cancer mortalities with around 13,000 mortalities in 2018. This is primarily due to the increasing aging population of UK. As per Cancer Research UK, more than half (54%) of prostate cancer cases in the UK each year are diagnosed in males aged 70 and over of age. Moreover, incidence rates for prostate cancer are projected to rise by 12% in the UK between 2014 and 2035 and 1 in 8 men will be diagnosed with prostate cancer during their lifetime in the country. Prostate cancer is most common in black males, then White males and least common in Asian males.

UK prostate cancer diagnostic and the rapeutics market has been studied on the basis of diagnostic techniques and therapeutics. By diagnosis technique, prostate biopsy is expected to hold a major market share during the forecast period. By therapeutics, chemotherapy is expected to have a major market share in the country. The companies which are contributing significantly in the market include Abbott Laboratories, AbbVie Products, LLC, AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Co., GlaxoSmithKline PLC, Johnson & Johnson, Pfizer Inc., Siemens Healthcare AG, and others. The market players are considerably contributing to the market growth by the adoption of various growth strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market. In January 2020, Scotland approved a new prostate cancer drug for the men diagnosed with metastatic prostate cancer. The drug is Abiraterone acetate, branded name Zytiga owned by Centocor Ortho Biotech Inc., a company of Johnson & Johnson.

A full report of UK Prostate Cancer Diagnostic and Therapeutic Market is available at https://www.omrglobal.com/industry-reports/uk-prostate-cancer-diagnostic-therapeutic-market

UK Prostate Cancer Market-Segmentation

By Diagnostic Techniques

o Prostate-Specific Antigen Test (PSA)
o Digital Rectal Examination
o Prostate Biopsy
o Imaging Techniques

By Therapeutics

o Hormonal Therapy
o Chemotherapy
o Immunotherapy
o Radiation Therapy
o Targeted Therapy
o Surgery

Company Profiles

o Abbott Laboratories
o AbbVie Products, LLC
o Amgen Inc.
o AstraZeneca PLC
o Bayer AG
o Bristol-Myers Squibb Co.
o Ferring Pharmaceuticals Inc.
o GlaxoSmithKline PLC
o Johnson & Johnson
o Pfizer Inc.

For more customized data, request for report customization @ https://www.omrglobal.com/report-customization/uk-prostate-cancer-diagnostic-therapeutic-market

Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. AnuragTiwari
Email: info@omrglobal.com
Contact no: +1 646-755-7667, +91 780-304-0404

About us:

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.